Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.53 |
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090663 | 0.88 | CNR2 (0.45) | CNR2CNR1MAPK14MAPK13MAPK12 | |
| SCHEMBL4093014 | 0.85 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL4095389 | 0.83 | CNR2 (0.41) | CNR2CNR1MAPK14RPS6KB1 | |
| SCHEMBL3752729 | 0.83 | CNR2 (0.41) | CNR2CNR1MAPK14RPS6KB1 | |
| SCHEMBL4083931 | 0.81 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL4091024 | 0.79 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL3648724 | 0.78 | CNR2 (0.47) | CNR2CNR1MAPK14 | |
| SCHEMBL3646430 | 0.77 | CNR2 (0.57) | CNR2CNR1RPS6KB1 | |
| SCHEMBL3679591 | 0.76 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL3686465 | 0.75 | CNR2 (0.51) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338623-B2 | N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885MAPK14 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.